**SUPPLEMENTARY DATA:**

**Supplementary tables:**

1. **Supplementary table 1**
2. **Supplementary table 2**

**This supplementary material has been provided by the authors to give readers additional information about their work.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table1. List of studies with information on regression analysis in AP** | | | | | | |
| S No. | **Author Year** | | **Information on regression analysis** | | | |
|  | **Asian Studies** | | | | | |
| 1 | Kondo 2014 | | Univariate and multivariate analyses for prognostic factors influencing cancer-specific survival were performed using the Cox proportional hazards model | | | |
| 2 | Lee 2015 | | Continuous variables were compared using the Mann– Whitney U-test. Kaplan–Meier estimates and the Cox proportional hazard model were used in the analysis of time-event variables. | | | |
| **Supplementary table 2. Hazards Ratio in the AP** | | | | | | | |
| **Asian Studies** | |  | |  |  |  | |
| **Author Year** | | **Variable** | | **Hazards ratio** | **95% CI** | **P value** | |
| Kondo 2014 | | Median PFS of Schedule 2/1 group> Schedule 4/2 group (n=48) | | 0.57 | 0.23–1.35 | 0.2 | |
|  | | **Prognostic factors influencing PFS (Multivariate analysis)** | | | | | |
|  | | Papillary subtype | | 17.23 | 1.98–122.2 | 0.01 | |
|  | | Prior nephrectomy | | 0.39 | 0.14–1.18 | 0.09 | |
|  | | Memorial Sloan-Kettering Cancer Centre poor risk | | 2.25 | 0.83–5.49 | 0.1 | |
|  | | Schedule 2/1 | | 0.57 | 0.23–1.35 | 0.2 | |
|  | | Age | | 7.22 | 0.48–135.7 | 0.15 | |
|  | |  | |  |  |  | |
| Lee 2015 | | Failure-free survival at 6 months (schedule 2/1 vs. schedule 4/2) | | 0.57 | 0.34 – 0.95 | 0.029 | |
|  | | Time to progression | | 0.75 | 0.44 – 1.27 |  | |
|  | | OS (schedule 2/1 vs. schedule 4/2) | | 1.15 | 0.64-2.04 |  | |
|  | | probability of dose reduction | | 0.35 | 0.16-0.61 | 0.014 | |

CI, Confidence Interval; PFS, Progression-free survival; OS, Overall survival